SEATTLE, WA — (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that… Read More
New method of use patent (U.S. Patent No. 11,622,991) issued for LUPKYNIS Reflects the unique and proprietary dosing regimen indicated for LUPKINIS in Lupus Nephritis Announcement is a follow-up to… Read More
PharmAla contracted Filament subsidiary Psilo Scientific to manufacture the drug product for distribution to clinical trial customers and authorized patients VANCOUVER, BC — PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a… Read More
With this approval, approximately 30 children with two copies of the F508del mutation are eligible for a medicine that treats the underlying cause of their disease for the first time… Read More
VANCOUVER, BC — (BUSINESS WIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of… Read More
